title: [GOOD PLANNING PRACTICE IN PRECLINICAL AND CLINICAL STUDIES OF UNFRACTIONATED AND FRACTIONATED HEPARINS IN RUSSIA AS THE BASIS OF SAFE AND EFFECTIVE ANTICOAGULATION THERAPY].
abstract: General principles of appropriate strategies for preclinical and clinical development of unfractionated and low-molecular-weight heparins and demonstration of their biosimilarity to corresponding reference medicinal products are provided. Demonstration of the biosimilarity of heparin-containing medicinal products constitutes the basis for their efficacy and safety during anticoagulation therapy. The main quality, safety, and efficacy characteristics of heparin products are described and the extent of non-clinical and clinical investigations necessary prior to drug marketing authorization are considered.
authors.forename: E V
authors.initials: EV
authors.lastname: Gavrishina
authors.forename: A V
authors.initials: AV
authors.lastname: Dobrovolskii
authors.forename: R R
authors.initials: RR
authors.lastname: Niyazov
authors.forename: D P
authors.initials: DP
authors.lastname: Romodanovskii
authors.forename: A N
authors.initials: AN
authors.lastname: Vasil'ev
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans
chemical_list: D000925:Anticoagulants; D006493:Heparin